Compare PRLB & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | PGEN |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2011 | 2013 |
| Metric | PRLB | PGEN |
|---|---|---|
| Price | $78.26 | $6.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $53.00 | $8.33 |
| AVG Volume (30 Days) | 173.2K | ★ 6.2M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ 0.71 | 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $8.56 | $1,115.92 |
| Revenue Next Year | $6.89 | $81.04 |
| P/E Ratio | ★ $112.76 | $231.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.10 | $2.99 |
| 52 Week High | $93.00 | $7.72 |
| Indicator | PRLB | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 55.27 |
| Support Level | $76.40 | $3.96 |
| Resistance Level | $82.41 | $7.32 |
| Average True Range (ATR) | 2.75 | 0.39 |
| MACD | -0.96 | -0.07 |
| Stochastic Oscillator | 10.84 | 51.38 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.